Biotech Stocks Move 50-200% on a Single Headline.
FuzeBio gives you the tools you need to spot opportunity in advance.
Clinical trials. FDA decisions. Pipeline breakthroughs. Our AI agents gather live information and translate complex drug data into clear investment signals you need to get ahead.
Try a popular ticker
Institutional-Grade Research Tools Designed For Clarity
Know What It's Worth
Our AI agents build Wall Street-grade valuation models in seconds. See fair value estimates with full methodology—rNPV, DCF, and comparables—all with adjustable assumptions.
- Bull, Base, Bear scenarios
- Adjustable inputs for your own analysis
Every Drug, Every Stage
Visualize the entire development pipeline at a glance. See which drugs are in preclinical, Phase 1, 2, 3, or approved—with key catalysts and timelines for each.
- Development stage tracking
- Upcoming catalysts highlighted
Understand the Science
Get detailed analysis on individual drugs—competitive positioning, key differentiators, clinical efficacy, and what it all means for the investment thesis.
- Competitive advantage analysis
- Plain English explanations
Research by Indication
Explore the competitive landscape for any disease. See market size, growth projections, treatment segments, and all the companies developing therapies.
- Total addressable market data
- Competitive landscape mapping
And more...
Catalyst calendars, competitor analysis, financial snapshots, bull & bear cases—everything you need to make informed decisions.
Try It NowSmart Money is Moving to Biotech
Average return on positive Phase 3 trial results
of hedge funds have biotech exposure
Pharma M&A war chest for buyouts
While everyone chases the same AI stocks, biotech offers asymmetric returns that tech can't match. A single FDA approval can 2-3x a stock overnight. The catch? Understanding the science. That's where we come in.
Your AI Research Team (No PhD Required)
Whether you're new to biotech or a seasoned investor, our AI agents handle the complexity so you can focus on decisions.
Translates the Science
You don't need to understand mRNA vs CRISPR vs gene therapy. Our AI reads the papers and tells you what matters for the stock.
Sources: SEC filings, ClinicalTrials.gov, PubMed, FDA databases
Calculates Fair Value
What's the stock actually worth? Our AI builds Wall Street-grade valuation models and shows you exactly how it got the number.
Methodology: rNPV, DCF, and trading comparables with adjustable inputs
Finds the Catalysts
Know what events could move the stock 50%+ and when they're happening. Never be blindsided by "surprise" FDA decisions again.
Tracks: PDUFA dates, AdCom meetings, data readouts, earnings
Gives You the Playbook
Get clear bull and bear cases with price targets. Know exactly what needs to go right—and what could go wrong.
Includes: Probability-weighted scenarios, sensitivity analysis
Everything You Need to Decide
Stop juggling seven browser tabs. Get complete biotech research in one place.
AI-Powered Price Targets
Real-time valuation using rNPV, DCF, and comparables. Adjust peak sales, probability of success, and discount rates—and watch the price target update instantly.
Bull & Bear Cases
Clear thesis statements for both sides of the trade, so you know the risks.
Catalyst Calendar
Upcoming FDA dates, trial readouts, and earnings—never miss a market-moving event.
Pipeline Analysis
Every drug candidate, trial phase, and target indication mapped out clearly.
Competitive Landscape
See who else is targeting the same indications and how they stack up.
Financial Snapshot
Cash runway, burn rate, and key metrics—know if they can fund their trials.
Real-Time Updates
Our agents pull fresh data every time—no stale databases or outdated info.
Join Thousands of Investors Getting an Edge
Already Know Biotech? Here's Why You'll Love This.
If you're already following PDUFA dates and parsing trial endpoints, you don't need the basics—you need speed. FuzeBio gives you:
- Drug-by-drug rNPV models with adjustable PoS and peak sales assumptions
- Sum-of-parts waterfall charts updated in real-time
- Sensitivity matrices across discount rates and probability scenarios
- All the data you'd pull manually, synthesized in seconds
Skip the 4-hour research process. Get straight to the model.
See a Sample ValuationHow We Compare
See how FuzeBio stacks up against the tools you're currently using
| Feature | FuzeBio$29/mo | Seeking Alpha$199/yr | Bloomberg$25k/yr | ChatGPT$20/mo |
|---|---|---|---|---|
Adjustable rNPV/DCF Models Drug-by-drug models with adjustable PoS, peak sales, discount rates | ||||
Plain English + Full Methodology Complex trial data explained clearly, with links to sources | ||||
Real-Time SEC, FDA, Clinical Data Live feeds from EDGAR, ClinicalTrials.gov, FDA databases | ||||
Hours of Research → Seconds Bull/bear cases, catalyst calendars, pipeline views—instantly | ||||
Biotech-Specific UI Built specifically for biotech research workflow | ||||
Affordable Pricing $29/mo vs. $25k/year for Bloomberg |
Biotech Doesn't Have to Be Complicated.
Start researching stocks in 30 seconds. No credit card. No PhD.